PMS Registry
In order to understand if there is other unknown side effect during the clinical trail, the PMS (Post-Marketing Study) will be conducted to learn more treatment experiences on patients, and collect their information for further study.
No. 9 of IRPMA COP Benchmarks regulates that all PMS shall go through JIRB, IRB or Ethics Committee and must be registered on the website of IRPMA PMS registry system. It is to ensure the studies conducted on patients have been approved by JIRB, IRB and protect patient’s right of privacy. The public can also get the information and objective of the PMS through the registry system.
Company Name
Title of Study
Update Date
Janssen, Jahnson & Johnson Multicenter observational drug registry of Opsumit® (macitentan) in connective tissue disease associated pulmonary arterial hypertension (CTD-PAH) in real world Taiwan clinical setting 2023-10-03
Bayer Taiwan Co., Ltd Systemic treatment patterns of hepatocellular carcinoma (HCC) in Taiwan 2023-08-24
Bayer Taiwan Co., Ltd Copanlisib in Indolent Non-Hodgkin Lymphoma Patients: A Real-world Taiwan Observation Multicenter Study 2023-08-24
Bayer Taiwan Co., Ltd Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients / DAROL 2023-06-20
GSK A Phase IV, Prospective, Non-Interventional Cohort Study of Fostemsavir Based Regimen In Heavily Treatment Experienced Patient With Hiv-1 Infection In Taiwan 2023-05-24
AbbVie Biopharmaceuticals GmbH Prospective Observational Cohort study of patients with moderate to severe chronic plaque psoriasis in Taiwan 2023-03-24
Gilead Sciences Hong Kong Ltd. Taiwan Branch A Post-Authorization Study to Evaluate Safety and Clinical Outcomes in COVID-19 Patients Treated with Veklury® (Remdesivir) in Taiwan 2023-01-06
Gilead Sciences Hong Kong Limited, Taiwan Branch Multi-country, non-interventional, cohort study of the effectiveness, safety, adherence, and health-related quality of life in HIV-1 infected adult patients receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Asia. 2023-01-06
Bayer Taiwan Co., Ltd. Observational study evaluating the physical activity in a subset of damoctocog alfa pegol treated Hemophilia A patients who are enrolled in the HEM-POWR study. 2022-11-29
Bayer Taiwan Co., Ltd. Observational Study Evaluating Effectiveness and Safety of Real-World Treatment with Damoctocog alfa pegol in Previously Treated Patients with Hemophilia A 2022-07-28
   1 2 3 4 5 6 7 8